Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with NonST-segment elevation acute coronary syndrome and low event rates

American Journal of Cardiology

Volumn 106, Issue 5, 2010, Pages 650-658

  Beygui, Farzin ^a   Silvain, Johanne ^a   Pena, Ana ^a   Bellemain Appaix, Anne ^a   Collet, Jean Philippe ^a   Drexler, Helmut ^b   Bhatt, Deepak ^c   Vicaut, Eric ^d   Montalescot, Gilles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF APPLIED SCIENCES AND ARTS   (Germany)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GELATINASE B; INTERLEUKIN 6; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; IRBESARTAN; TETRAZOLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TETRAZOLES;

EID: 77955924310     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.04.019     Document Type: Article

References (28)

1. K.A. Fox, O.H. Dabbous, R.J. Goldberg, K.S. Pieper, K.A. Eagle, F. Van de Werf, A. Avezum, S.G. Goodman, M.D. Flather, F.A. Anderson Jr, and C.B. Granger Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 333 2006 1091
2. K.A. Eagle, M.J. Lim, O.H. Dabbous, K.S. Pieper, R.J. Goldberg, F. Van de Werf, S.G. Goodman, C.B. Granger, P.G. Steg, J.M. Gore, A. Budaj, A. Avezum, M.D. Flather, and K.A. Fox A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733 (Pubitemid 38725422)
3. L.M. Biasucci, G. Liuzzo, R.L. Grillo, G. Caligiuri, A.G. Rebuzzi, A. Buffon, F. Summaria, F. Ginnetti, G. Fadda, and A. Maseri Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability Circulation 99 1999 855 860
4. M. Hartford, O. Wiklund, L. Mattsson Hulten, A. Persson, T. Karlsson, J. Herlitz, and K. Caidahl C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes J Intern Med 262 2007 526 536
5. B. Lindahl, H. Toss, A. Siegbahn, P. Venge, and L. Wallentin Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease N Engl J Med 343 2000 1139 1147
6. G. Liuzzo, L.M. Biasucci, J.R. Gallimore, R.L. Grillo, A.G. Rebuzzi, M.B. Pepys, and A. Maseri The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina N Engl J Med 331 1994 417 424
7. C. Mueller, H.J. Buettner, J.M. Hodgson, S. Marsch, A.P. Perruchoud, H. Roskamm, and F.J. Neumann Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients Circulation 105 2002 1412 1415
8. L.S. Rallidis, M.G. Zolindaki, H.S. Manioudaki, N.P. Laoutaris, A.H. Velissaridou, and E.G. Papasteriadis Prognostic value of C-reactive protein, fibrinogen, interleukin-6, and macrophage colony stimulating factor in severe unstable angina Clin Cardiol 25 2002 505 510
9. P.G. Steg, P. Ravaud, A. Tedgui, J. Puel, D. Moyse, E. Curaudeau, and S.W. Quentzel Predischarge C-reactive protein and 1-year outcome after acute coronary syndromes Am J Med 119 2006 684 692
10. L.M. Biasucci, G. Liuzzo, G. Fantuzzi, G. Caligiuri, A.G. Rebuzzi, F. Ginnetti, C.A. Dinarello, and A. Maseri Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events Circulation 99 1999 2079 2084
11. E. Lindmark, E. Diderholm, L. Wallentin, and A. Siegbahn Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy JAMA 286 2001 2107 2113
12. M.L. Brennan, M.S. Penn, F. Van Lente, V. Nambi, M.H. Shishehbor, R.J. Aviles, M. Goormastic, M.L. Pepoy, E.S. McErlean, E.J. Topol, S.E. Nissen, and S.L. Hazen Prognostic value of myeloperoxidase in patients with chest pain N Engl J Med 349 2003 1595 1604
13. M.K. Sinha, D.C. Gaze, J.R. Tippins, P.O. Collinson, and J.C. Kaski Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention Circulation 107 2003 2403 2405
14. Z. Mallat, P.G. Steg, J. Benessiano, M.L. Tanguy, K.A. Fox, J.P. Collet, O.H. Dabbous, P. Henry, K.F. Carruthers, A. Dauphin, C.S. Arguelles, J. Masliah, B. Hugel, G. Montalescot, J.M. Freyssinet, B. Asselain, and A. Tedgui Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes J Am Coll Cardiol 46 2005 1249 1257
15. S. Blankenberg, H.J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, G. Hafner, J. Meyer, F. Cambien, and L. Tiret Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease Circulation 107 2003 1579 1585
16. D. Kelly, S.Q. Khan, M. Thompson, G. Cockerill, L.L. Ng, N. Samani, and I.B. Squire Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction Eur Heart J 29 2008 2116 2124
17. C. Heeschen, S. Dimmeler, C.W. Hamm, M.J. van den Brand, E. Boersma, A.M. Zeiher, and M.L. Simoons Soluble CD40 ligand in acute coronary syndromes N Engl J Med 348 2003 1104 1111
18. J.L. Mega, D.A. Morrow, J.A. De Lemos, M.S. Sabatine, S.A. Murphy, N. Rifai, C.M. Gibson, E.M. Antman, and E. Braunwald B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy J Am Coll Cardiol 44 2004 335 339 (Pubitemid 38950592)
19. A.M. Richards, M.G. Nicholls, E.A. Espiner, J.G. Lainchbury, R.W. Troughton, J. Elliott, C. Frampton, J. Turner, I.G. Crozier, and T.G. Yandle B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction Circulation 107 2003 2786 2792
20. F. Beygui, J.P. Collet, J.J. Benoliel, N. Vignolles, R. Dumaine, O. Barthelemy, and G. Montalescot High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction Circulation 114 2006 2604 2610
21. F. Beygui, G. Montalescot, E. Vicaut, S. Rouanet, E. Van Belle, C. Baulac, A. Degrandsart, and J. Dallongeville Aldosterone and long-term outcome after myocardial infarction: a substudy of the French nationwide Observatoire sur la Prise en charge hospitaliere, l'Evolution a un an et les caRacteristiques de patients presentant un infArctus du myocarde avec ou sans onde Q (OPERA) study Am Heart J 157 2009 680 687
22. B.R. Palmer, A.P. Pilbrow, C.M. Frampton, T.G. Yandle, L. Skelton, M.G. Nicholls, and A.M. Richards Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction Eur Heart J 29 2008 2489 2496
23. G. Montalescot, H. Drexler, R. Gallo, T. Pearson, M. Thoenes, and D.L. Bhatt Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study Eur Heart J 30 2009 2733 2741
24. P.G. Steg, L. Joubin, J. McCord, W.T. Abraham, J.E. Hollander, T. Omland, F. Mentre, P.A. McCullough, and A.S. Maisel B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea Chest 128 2005 21 29
25. D.S. Ang, L. Wei, M.P. Kao, C.C. Lang, and A.D. Struthers A comparison between B-type natriuretic peptide, Global Registry of ACUTE CORONARY EVENTS (GRACE) score and their combination in ACS risk stratification Heart 95 2009 1836 1842
26. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, and M. Gatlin Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
27. M.M. Thompson, and I.B. Squire Matrix metalloproteinase-9 expression after myocardial infarction: physiological or pathological? Cardiovasc Res 54 2002 495 498
28. I.B. Squire, J. Evans, L.L. Ng, I.M. Loftus, and M.M. Thompson Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction J Card Fail 10 2004 328 333